Can paroxetine cause Gout? A question that is being studied constantly and at this stage it is generally known that this drug can be very dangerous for sufferers of Gout especially if they are on any drug or herb to combat or maintain Gout
Paraoxetine is a drug that is a derivative of phenylpiperidine, it is a potent drug used in patients suffering from depression, compulsive disorders, panic disorders, and symptoms of post-traumatic stress disorders.
Most importantly there can be suicidal tendencies associated with this drug.
The dosages vary from 10mg a day up to 60mg per day pending the patients history and disorder. Paraoxetine should not be used during pregnancy, epileptics need to be very careful, or people with renal or heart disease as this can have severe consequences such as death or heart attacks. The drug should not be abruptly stopped due to potent withdrawal symptoms, but be gradually withdrawn as to not effect a patient. Some symptoms of taking paraoxetine may mimic that of Gout symptoms such as sweating, chills, temperature fluctuations , swelling of the hands and feet and toe areas and cause low blood pressure which in turn starts an avalanche of symptoms throughout the body. Can paroxetine cause gout? It can certainly affect a sufferer's chances of having a gout attack or severely affecting the function of the Liver and kidneys which in turn can have detrimental effects on a Gout attack. It is known to effect the body's metabolism - and has a warning of potential weight gain / loss / dehydration which is not what a gout sufferer wants to happen fast. I strongly suggest that if you are going to take this drug that you inform your doctor or practitioner of other medications you are on , including any herbs or tonics, plus you "MUST" ask your practitioner about side effects and long term dangers of this drug.
Can paroxetine cause Gout?
read on my friends and decide your self.
Now here is an interesting list of side effects supplied from Drugs.com and you can see why I always suggest asking your doctor / medial practitioner what are the side effect from the drugs suggested by them....it is scary what can happen when we just take what we are told without knowing the ramifications.
If any of the following side effects occur while taking paroxetine, check with your doctor immediately:
Incidence not known:
Some paroxetine side effects may not need any medical attention. As your body gets used to the medicine these side effects may disappear. Your health care professional may be able to help you prevent or reduce these side effects, but do check with them if any of the following side effects continue, or if you are concerned about them:
For Healthcare Professionals
Applies to paroxetine: oral capsule, oral suspension, oral tablet, oral tablet extended release -
Can paroxetine cause Gout?
effects are generally reported as mild. The most common side effects
associated with treatment discontinuation in clinical trials included
somnolence, insomnia, agitation, tremor, anxiety, dizziness, headache,
constipation, nausea, diarrhea, dry mouth, vomiting, flatulence,
asthenia, abnormal ejaculation, sweating, impotence, and decreased
The most common dose-dependent side effects associated with treatment discontinuation in clinical trials for the treatment of premenstrual dysphoric disorder with controlled-release paroxetine 25 mg compared with 12.5 mg included nausea, somnolence, impaired concentration, dry mouth, dizziness, decreased appetite, sweating, tremor, and yawn.
The most common side effects associated with treatment discontinuation in the treatment of vasomotor symptoms in clinical trials included abdominal pain, attention disturbances, headache, and suicidal ideation.
In a placebo-controlled study in elderly patients with major depressive disorder, the most common side effects associated with treatment discontinuation of controlled-release paroxetine included nausea, headache, depression, and abnormal LFTs.
There may be adaptation to some side effects (such as nausea and dizziness) but not to others (such as dry mouth, somnolence, and asthenia) with continued therapy. Paroxetine is less likely than tricyclic antidepressants to be associated with dry mouth, constipation, and somnolence.
Very common (10% or more): Insomnia
Common (1% to 10%): Abnormal dreams, agitation, anxiety, depersonalization, depression, drugged feeling, emotional lability, lack of emotion, nervousness
Uncommon (0.1% to 1%): Abnormal thinking, alcohol abuse, bruxism, euphoria, hallucinations, hostility, lack of emotion, manic reaction, neurosis, paranoid reaction
Rare (less than 0.1%): Abnormal electroencephalogram, antisocial reaction, bulimia, delirium, delusions, drug dependence, hysteria, irritability, manic-depressive reaction, panic attacks, psychosis, psychotic depression, stupor, withdrawal syndrome
Frequency not reported: Suicidal ideation and behavior
Postmarketing reports: Confusional state, disorientation, homicidal ideation, restlessness
may have a role in inducing worsening of depression and the emergence
of suicidality in certain patients during the early phases of treatment.
An increased risk of suicidal thinking and behavior in children,
adolescents, and young adults (aged 18 to 24 years) with major
depressive disorder (MDD) and other psychiatric disorders has been
reported with short-term use of antidepressant drugs.
Adult and pediatric patients receiving antidepressants for MDD, as well as for psychiatric and nonpsychiatric indications, have reported symptoms that may be precursors to emerging suicidality, including anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, hypomania, and mania. Causality has not been established.
Pooled results from clinical trials report hallucinations in 22 of 9089 patients who received paroxetine and 4 of 3187 patients who received placebo.
symptoms such as akathisia, bradykinesia, cogwheel rigidity, dystonia,
hypertonia, and oculogyric crisis have been associated with concomitant
Potentially life-threatening serotonin syndrome has been reported with SSRIs and SNRIs as monotherapy, but particularly with concomitant use of other serotonergic drugs and drugs that impair the metabolism of serotonin. Signs and symptoms associated with serotonin syndrome or neuroleptic malignant syndrome included agitation, confusion, diaphoresis, diarrhea, fever, hypertension, rigidity, and tachycardia, and were in some cases associated with concomitant use of serotonergic drugs.
Very common (10% or more): Dizziness, headache, somnolence, tremor
Common (1% to 10%): Amnesia, anxiety, CNS stimulation, confusion, hypertonia, impaired concentration, migraine, myoclonus, paresthesia, taste perversion
Uncommon (0.1% to 1%): Ataxia, convulsion, dyskinesia, dystonia, hyperesthesia, hyperkinesia, hypokinesia, incoordination, neuralgia, neuropathy, nystagmus, paralysis, syncope
Rare (less than 0.1%): Abnormal gait, adrenergic syndrome, akathisia, akinesia, anticholinergic syndrome, aphasia, cerebral ischemia, cerebrovascular accident, choreoathetosis, circumoral paresthesia, dysarthria, extrapyramidal syndrome, fasciculations, grand mal convulsions, hyperalgesia, meningitis, myelitis, peripheral neuritis, reflexes decreased, reflexes increased, taste loss, torticollis, trismus, vascular headache
Postmarketing reports: Eclampsia, Guillain-Barre syndrome, neuroleptic malignant syndrome, restless legs syndrome, serotonin syndrome, status epilepticus
results of one study appear to indicate that treatment with selective
serotonin reuptake inhibitors (i.e., paroxetine, sertraline, citalopram)
may cause an increase in serum total cholesterol, HDL cholesterol,
and/or LDL cholesterol. However, additional studies are necessary to
confirm these findings.
Numerous cases of hyponatremia have been reported following treatment with a selective serotonin reuptake inhibitor (SSRI). Risk factors for the development of SSRI- associated hyponatremia including advanced age, female gender, concomitant use of diuretics, low body weight, and lower baseline serum sodium levels have been identified. Hyponatremia tends to develop within the first few weeks of treatment (range 3 to 120 days) and typically resolves within 2 weeks (range 48 hours to 6 weeks) after therapy has been discontinued with some patients requiring treatment. The proposed mechanism for the development of hyponatremia involves the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) via release of antidiuretic hormone.
Common (1% to 10%): Decreased appetite, increased appetite, increases in cholesterol levels, weight gain, weight loss
Uncommon (0.1% to 1%): Hypoglycemia, hypokalemia, thirst
Rare (less than 0.1%): Alkaline phosphatase increased, creatinine phosphokinase increased, dehydration, diabetes mellitus, gamma globulins increased, gout, hypercalcemia, hypercholesteremia, hyperglycemia, hyperkalemia, hyperphosphatemia, hypocalcemia, hyponatremia, ketosis, lactic dehydrogenase increased, non-protein nitrogen increased, obesity
Postmarketing reports: Porphyria
Common (1% to 10%): Chest pain, edema, palpitation, peripheral edema, tachycardia, vasodilation (usually flushing)
Uncommon (0.1% to 1%): Abnormal electrocardiogram, angina pectoris, bradycardia, conduction abnormalities, hematoma, hypertension, hypotension, palpitation, postural hypotension, sinus tachycardia, supraventricular tachycardia
Rare (less than 0.1%): Arrhythmia, arrhythmia nodal, atrial arrhythmia, atrial fibrillation, bundle branch block, cellulitis, congestive heart failure, extrasystoles, heart block, low cardiac output, myocardial infarct, myocardial ischemia, pallor, phlebitis, substernal chest pain, supraventricular extrasystoles, thrombophlebitis, thrombosis, varicose vein, ventricular extrasystoles
Postmarketing reports: Atrial fibrillation, pulmonary edema, ventricular fibrillation, ventricular tachycardia (including torsades de pointes)
Fatigue, malaise, and lethargy were very commonly reported in Phase 2 and 3 clinical trials with paroxetine for treatment of vasomotor symptoms in postmenopausal women.
Very common (10% or more): Asthenia
Common (1% to 10%): Chills, pain, tinnitus, trauma, vertigo
Uncommon (0.1% to 1%): Ear pain, fever, malaise, otitis media, overdose
Rare (less than 0.1%): Abscess, deafness, hypothermia, otitis externa, sepsis, ulcer, abnormal laboratory value, cyst, hernia, intentional overdose
Postmarketing reports: Death.
Very common (10% or more): Decreased libido, ejaculation disturbance, other male genital disorders (primarily ejaculatory delay)
Common (1% to 10%): Female genital disorders (primarily anorgasmia and difficulty reaching climax/orgasm), dysmenorrhea, impotence, menorrhagia, menstrual disorder, urinary disorder (primarily difficulty with micturition and urinary hesitancy), urinary frequency, urination impaired, urinary tract infection, vaginal moniliasis, vaginitis
Uncommon (0.1% to 1%): Albuminuria, amenorrhea, breast pain, cystitis, dysuria, hematuria, increased libido, nocturia, ovarian cyst, polyuria, pyuria, pregnancy and puerperal disorders, testes pain, urinary incontinence, urinary retention, urinary urgency,
Rare (0.01% to 0.1%): Abortion, breast atrophy, breast enlargement, endometrial disorder, epididymitis, female lactation, fibrocystic breast, kidney calculus, kidney pain, leukorrhea, mastitis, metrorrhagia, nephritis, oliguria, pelvic pain, salpingitis, urethritis, urinary abnormality, urinary casts, uterine spasm, urolith, vaginal hemorrhage
Very rare (less than 0.01%): Priapism
Postmarketing reports: Premature births in pregnant women, symptoms suggestive of galactorrhea.
are several reports of priapism associated with paroxetine use. In
cases in which outcome was reported, all patients fully recovered.
In placebo-controlled clinical trials, ejaculatory disturbance in men was reported in 13% to 28% of men taking paroxetine, compared to 0% to 2% in the placebo group. Decreased libido was reported in 6% to 15% in men treated with paroxetine, compared to 0% to 5% in the placebo group, and in 0% to 9% in women treated with paroxetine, compared with 0% to 2% in placebo patients. The estimates of the incidence of untoward sexual experience and performance may underestimate their actual incidence, partly because patients and physicians may be reluctant to discuss this issue.
Seven cases of alopecia have been reported. In all cases, hair loss was eventually reversible.
A case of cutaneous leukocytoclastic vasculitis has been reported following treatment with paroxetine. The patient originally developed the lesions after treatment with escitalopram. The lesions disappeared one week following discontinuation of escitalopram and reappeared upon rechallenge. When the patient was switched to paroxetine a similar reaction occurred.
Very common (10% or more): Sweating
Common (1% to 10%): Eczema, hypertension, photosensitivity, pruritus, rash, sweat gland disorder
Uncommon (0.1% to 1%): Acne, alopecia, contact dermatitis, dry skin, ecchymosis, furunculosis, purpura, urticaria
Rare (0.01% to 0.1%): Angioedema, erythema multiforme, erythema nodosum, exfoliative dermatitis, fungal dermatitis, hirsutism, maculopapular rash, pustular rash, seborrhea, skin discoloration, skin hypertrophy, skin ulcer, sweating decreased, vesiculobullous rash
Very rare (less than 0.01%): Severe cutaneous reactions such as Stevens Johnson syndrome and toxic epidermal necrolysis)
Postmarketing reports: Vasculitic syndromes (such as Henoch-Schonlein purpura).
Rare (less than 0.1%): Goiter, hyperthyroidism, hypothyroidism, thyroiditis
Postmarketing reports: Syndrome of inappropriate antidiuretic hormone secretion, symptoms suggestive of prolactinemia
A study of 26,005 antidepressant users has reported 3.6 times more upper GI bleeding episodes with the use of SSRIs relative to the population who did not receive antidepressant medications. Upper gastrointestinal tract bleeding was observed up to 3.2 times more frequently in patients receiving paroxetine.
Very common (10% or more): Constipation, diarrhea, dry mouth, nausea
Common (1% to 10%): Abdominal pain, dyspepsia, flatulence, gastrointestinal disorder, gingivitis, stomatitis, tooth disorder, vomiting
Uncommon (0.1% to 1%): Buccal cavity disorders, colitis, dysphagia, eructation, gastritis, gastroenteritis, gastroesophageal reflux, gastrointestinal flu, gingivitis, glossitis, increased salivation, melena, pancreatitis, rectal hemorrhage, toothache, ulcerative stomatitis
Rare (less than 0.1%): Aphthous stomatitis, bloody diarrhea, cardiospasm, cholelithiasis, duodenitis, enteritis, esophagitis, fecal impaction, fecal incontinence, gum hemorrhage, gum hyperplasia, hematemesis, ileitis, ileus, intestinal obstruction, mouth ulceration, peptic ulcer, peritonitis, salivary gland enlargement, sialadenitis, stomach ulcer, tooth caries, tongue discoloration, tongue edema, tooth malformation
Postmarketing reports: Acute pancreatitis, pancreatitis hemorrhagic.
Uncommon (0.1% to 1%): Anemia, eosinophilia, hypochromic anemia, leukocytosis, leukopenia, lymphadenopathy, WBC abnormality
Rare (less than 0.1%): Abnormal erythrocytes, abnormal lymphocytes, anisocytosis, basophilia, bleeding time increased, iron deficiency anemia, lymphedema, lymphocytosis, lymphopenia, microcytic anemia, monocytosis, normocytic anemia, thrombocytopenia, thrombocythemia,
Postmarketing reports: Events related to impaired hematopoiesis (including aplastic anemia, pancytopenia, bone marrow aplasia, agranulocytosis), hemolytic anemia, idiopathic thrombocytopenic purpura
Uncommon (0.1% to 1%): Abnormal liver function tests, SGOT increased, SGPT increased
Rare (less than 0.1%): Bilirubinemia, hepatitis, hepatosplenomegaly, jaundice
Postmarketing reports: Drug-induced liver injury, elevated liver function tests, hepatic failure.
In placebo-controlled clinical trials patients receiving paroxetine experienced abnormal values on liver function tests at a rate equal to or less than that reported in patients receiving placebo. However, there have been postmarketing reports of patients developing elevated serum transaminases resulting in severe liver dysfunction, as well as, a few cases of elevated liver function tests resulting in death secondary to liver necrosis.
Uncommon (0.1% to 1%): Allergic reaction, face edema
Rare (less than 0.1%): Anaphylactoid reaction
Postmarketing reports: Anaphylaxis.
Common (1% to 10%): Infection
Uncommon (0.1% to 1%): Flu syndrome, herpes simplex
Rare (less than 0.1%): Herpes zoster, moniliasis.
Epidemiological studies, primarily in patients aged 50 years or older, have shown an increased risk of bone fractures in patients receiving SSRIs or TCAs.
Common (1% to 10%): Arthralgia, back pain, migraine, myalgia, myasthenia, myopathy
Uncommon (0.1% to 1%): Arthritis, arthrosis, bursitis, myositis, neck pain, tendonitis, traumatic fracture
Rare (less than 0.1%): Cartilage disorder, generalized spasm, myositis, neck rigidity, osteoporosis, tenosynovitis, tetany.
Common (1% to 10%): Abnormality of accommodation, abnormal vision, blurred vision
Uncommon (0.1% to 1%): Conjunctivitis, eye pain, keratoconjunctivitis, mydriasis, photophobia, retinal hemorrhage
Rare (less than 0.1%): Anisocoria, blepharitis, cataract, conjunctival edema, corneal lesion, corneal ulcer, diplopia, exophthalmos, eye hemorrhage, glaucoma, hyperacusis, night blindness, ptosis, visual field defect
Frequency not reported: Angle-closure glaucoma, eye pain
Postmarketing reports: Acute glaucoma, optic neuritis.
Rare (less than 0.1%): Abnormal kidney function, BUN increased
Postmarketing reports: Acute renal failure[Ref]
(1% to 10%): Bronchitis, cough increased, oropharynx disorder,
pharyngitis, respiratory disorder, rhinitis, sinusitis, yawn
Uncommon (0.1% to 1%): Asthma, dyspnea, epistaxis, hyperventilation, laryngitis, pneumonia, respiratory flu
Rare (less than 0.1%): Dysphonia, emphysema, hemoptysis, hiccups, lung fibrosis, parosmia, pulmonary edema, pulmonary embolus, sputum increased, stridor, throat tightness, voice alteration
Postmarketing reports: Allergic alveolitis, laryngismus, pulmonary hypertension.
References1. "Product Information. Pexeva (PARoxetine)." Synthon Pharmaceuticals Ltd, Chapel Hill, NC. 2. "Product Information. Paxil CR (paroxetine)." SmithKline Beecham, Philadelphia, PA. 3. Cerner Multum, Inc. "Australian Product Information." O 04. "Product Information. Brisdelle (PARoxetine)." Noven Pharmaceuticals, Inc., New York, NY. 5. "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC. 6. Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992): 61-67. Staner L, Kerkhofs M, Detroux D, Leyman S, Linkowski P, Mendlewicz J "Acute, subchronic and withdrawal sleep EEG changes during treatment with paroxetine and amitriptyline: a double-blind randomized trial in major depression." Sleep 18 (1995): 470-78. Adler LA, Angrist BM "Paroxetine and akathisia." Biol Psychiatry 37 (1995): 336-79. Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S "Rare case of serotonin syndrome with therapeutic doses of paroxetine." Am J Ther 13 (2006): 550-55210. Patkar AA, Masand PS, Krulewicz S, et al. "A randomized, controlled, trial of controlled release paroxetine in fibromyalgia." Am J Med 120 (2007): 448-5411. Fava GA, Grandi S "Withdrawal syndromes after paroxetine and sertraline discontinuation." J Clin Psychopharmacol 15 (1995): 374-512. Bloch M, Stager SV, Braun AR, Rubinow DR "Severe psychiatric symptoms associated with paroxetine withdrawal." Lancet 346 (1995): 5713. Phillips SD "Possible paroxetine withdrawal syndrome." Am J Psychiatry 152 (1995): 645-614. Jacob S, Spinler SA "Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults." Ann Pharmacother 40 (2006): 1618-2215. Herran A, Ramirez ML, Carrera M, et al. "Panic disorder, treatment with selective serotonin reuptake inhibitors, and cholesterol levels." J Clin Psychopharmacol 26 (2006): 538-4016. Rothschild AJ "Sexual side effects of antidepressants." J Clin Psychiatry 61 (2000): 28-3617. Ahmad S "Paroxetine-induced priapism." Arch Intern Med 155 (1995): 64518. Flores-Suarez LF, Vega-Memije ME, Chanussot-Deprez C "Cutaneous vasculitis during selective serotonin reuptake inhibitor therapy." Am J Med 119 (2006): e1-319. Ahmed R, Eagleton C "Toxic epidermal necrolysis after paroxetine treatment." N Z Med J 121 (2008): 86-920. Margolese HC, Chouinard G, Beauclair L, Rubino M "Cutaneous vasculitis induced by paroxetine." Am J Psychiat 158 (2001): 49721. Gautam M "Alopecia due to psychotropic medications." Ann Pharmacother 33 (1999): 631-722. Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993): 14323. Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995): 39024. Madhusoodanan S, Brenner R, Brafman I, Bogunovic O "Hyponatremia associated with paroxetine use." South Med J 92 (1999): 84325. Odeh M, Seligmann H, Oliven A "Severe life-threatening hyponatremia during paroxetine therapy." J Clin Pharmacol 39 (1999): 1290-126. van Campen JP, Voets AJ "SIADH caused by paroxetine." Ann Pharmacother 30 (1996): 149927. Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992): 133228. Spigset O, hedenmalm K "Hyponatremia in relation to treatment with antidepressants: a survey of reports in the World Health Organization data base for spontaneous reporting of adverse drug reactions." Pharmacotherapy 17 (1997): 348-5229. Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH "Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study." Arch Intern Med 163 (2003): 59-6430. Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994): 781-231. Odeh M, Misselevech I, Boss JH, Oliven A "Severe hepatotoxicity with jaundice associated with paroxetine." Am J Gastroenterol 96 (2001): 2494-632. Liu B, Anderson G, Mittmann N, To Teresa, Axcell T, Shear N "Use of selective serotonin-reuptake inhibitors or tricyclic antidepressants and risk of hip fractures in elderly people." Lancet 351 (1998): 1303-7
Always seek medical advice before going ahead with any drug.
Always seek medical advice with regards to Gout, and Arthritis.
Be Gout Aware.
After reading this, it makes me wonder how much of the world has some of these side effects and live with them daily not knowing where they came from, and why the hell are we told of the side effects.
Can paroxetine cause Gout? well i wouldn't be taking this drug anyway, because more than likely it will interfere with any gout medication, or will increase side effects that will make your lifestyle difficult.
Yet again, please seek medical advice for your gout, and inform your doctor about current medicines you are on so you don't get detrimental side effects by mixing medicines.
Oct 01, 19 09:03 AM
I had some silver & out of desperation poured a lot in a bucket h soaked my gout foot. Pain subsided within15 mins. I've soaked b4 without this reaction.
Jul 16, 19 05:51 AM
I had not had gout in years. While on vacation, we bought some multigrain bread. Within a couple of days I had an attack of gout in toes on right foot.
May 09, 19 01:30 AM
I used to get gout flare up when I was in my thirties. They occurred every Christmas time. I would get knees so painful that I could not walk. After some